The EMPACT-MI (A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Myocardial Infarction)52 and DAPA-MI (Dapagliflozin Effects on Cardiovascular Events in Patients With an Acute Heart Attack)53 trials are ongoing trials that are evaluating the primary end point of HF hospitalizations and all-cause mortality with SGLT2 inhibitor use after myocardial infarction. This evidence concerns the gene SLC5A2 and heart failure.